Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

• Manali Kamdar,
• Hongli Li,
• Robert W. Chen,
• Lisa M. Rimsza,
• Michael L. Leblanc,
• Timothy S. Fenske,
• Thomas C. Shea,
• Paul M. Barr,
• Tycel J. Phillips,
• John P. Leonard,
• Brad S. Kahl,
• Jonathan W. Friedberg,
• Sonali M. Smith

Affiliations

Manali Kamdar

Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Denver, CO;; Manali Kamdar, University of Colorado, 1665 Aurora Ct, MSF754, Aurora, CO 80045;

Hongli Li

SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA;

Robert W. Chen

Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA;

Lisa M. Rimsza

Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ;

Michael L. Leblanc

SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA;

Timothy S. Fenske

Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI;

Thomas C. Shea

Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC;

Paul M. Barr

James P. Wilmot Cancer Center, Division of Hematology and Oncology, University of Rochester, Rochester, NY;

Tycel J. Phillips

Division of Hematology and Oncology, University of Michigan Cancer Center, Dexter, MI;

John P. Leonard

Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY;

Brad S. Kahl

Department of Medicine, Washington University School of Medicine, St. Louis, MO;

Jonathan W. Friedberg

Wilmot Cancer Institute, University of Rochester, Rochester, NY

Sonali M. Smith

Section of Hematology/Oncology, University of Chicago, Chicago, IL